Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Alternative Treatment Options for Older Patients With AML

In a debate at the 2019 Lymphoma & Myeloma Congress, Sangmin Lee, MD, Weill Cornell Medicine and New, New York, NY, argued that venetoclax combined with azacitidine, decitabine, and LDAC, should not be the new standard of care for AML patients aged ≥60 years.

 

 

Advertisement

Advertisement

Advertisement

Advertisement